Latest Hepatic encephalopathy Stories
PARIS, March 1, 2011 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE:BMY) announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 for use in adult patients with CHB with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine...
A pair of clinical trials, conducted in part at the University of North Carolina at Chapel Hill, found that two weeks of treatment with rifaximin provides significant relief of irritable bowel syndrome symptoms including bloating, abdominal pain and loose or watery stools.
From constipation and diarrhea to bloating and abdominal pain, the estimated 30 million victims of irritable bowel syndrome in the United States have it tough.
SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis.
Impairments more severe than early-stage Alzheimer's disease.
Results confirm earlier Cedars-Sinai studies showing effectiveness of rifaximin against chronic IBS.
NEW ORLEANS, May 3 /PRNewswire/ -- Ocera Therapeutics, Inc. presented today an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients at Digestive Disease Week (DDW), the annual meeting of the American Gastroenterological Association.
NEW ORLEANS, May 3 /PRNewswire/ -- Ocera Therapeutics, Inc.
Presence and type of complications predictors of mortality.
Results show limited survival advantage, only in specific patient types.
- A woman chauffeur.
- A woman who operates an automobile.